BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18155897)

  • 1. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer.
    Sharma R; Hook J; Kumar M; Gabra H
    Eur J Cancer; 2008 Jan; 44(2):251-6. PubMed ID: 18155897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
    Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
    Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.
    Ramsey S; Lamb GW; Aitchison M; Graham J; McMillan DC
    Cancer; 2007 Jan; 109(2):205-12. PubMed ID: 17149754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma.
    Kobayashi T; Teruya M; Kishiki T; Endo D; Takenaka Y; Tanaka H; Miki K; Kobayashi K; Morita K
    Surgery; 2008 Nov; 144(5):729-35. PubMed ID: 19081014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Kubota K
    Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Horie T; Kubota K
    Ann Surg; 2007 Dec; 246(6):1047-51. PubMed ID: 18043109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival.
    Read JA; Choy ST; Beale PJ; Clarke SJ
    Nutr Cancer; 2006; 55(1):78-85. PubMed ID: 16965244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer.
    Glen P; Jamieson NB; McMillan DC; Carter R; Imrie CW; McKay CJ
    Pancreatology; 2006; 6(5):450-3. PubMed ID: 16847382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
    J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
    Ramsey S; Aitchison M; Graham J; McMillan DC
    BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy.
    Kunisaki C; Takahashi M; Ono HA; Oshima T; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
    Oncology; 2012; 83(4):183-91. PubMed ID: 22890015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
    Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
    Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer.
    Crozier JE; Leitch EF; McKee RF; Anderson JH; Horgan PG; McMillan DC
    Am J Surg; 2009 Apr; 197(4):544-9. PubMed ID: 18614139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer.
    Ishizuka M; Kita J; Shimoda M; Rokkaku K; Kato M; Sawada T; Kubota K
    J Surg Oncol; 2009 Jul; 100(1):38-42. PubMed ID: 19399786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
    Dorn J; Schmitt M; Kates R; Schmalfeldt B; Kiechle M; Scorilas A; Diamandis EP; Harbeck N
    Clin Cancer Res; 2007 Mar; 13(6):1742-8. PubMed ID: 17363527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
    Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
    Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer.
    Jeong JH; Lim SM; Yun JY; Rhee GW; Lim JY; Cho JY; Kim YR
    Oncology; 2012; 83(5):292-9. PubMed ID: 22964877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.